Our team comprises a diverse mix of expertise across life sciences and strategic business management. The Senior Engagement Team reflects over 100 combined years of pharmaceutical and biotech industry experience including roles in R&D, strategic planning, marketing, finance and business development. Please click on the names below to find out more about some of our Senior Engagement Team.
David leads a multi-disciplinary team focusing on the provision of customized solutions to leading players in the pharmaceutical and biotechnology industries in key areas such as opportunity assessment and forecasting, lifecycle management, and market disruptions. He remains active in business development and project delivery.
Prior to this he led the groups’ opportunity assessment and forecasting offering, which included BD&L assessments, project and product evaluations, commercial due diligence, and market entry strategies for a number of top 25 pharmaceutical companies.
Prior to joining Datamonitor Healthcare Consulting, David held various managerial roles in business development and marketing in a division of Merck and Co. Before this he worked for a leading healthcare system in New York City, providing financial analysis and decision support.
David holds and MPA in Health Care Finance from New York University.
Jacqueline joined Datamonitor Healthcare Consulting in October 2003 from Cambridge Pharma Consultancy (now IMS Consulting), where she focused on pharmaceutical pricing and reimbursement strategy.
During her time at Datamonitor, Jacqueline has managed various strategic pharmaceutical and biotech consulting projects covering both major and emerging markets. She is currently responsible for driving business development and managing project delivery. Areas of expertise include commercial assessments, forecasting, and prioritization in support of product development, BD&L, and portfolio management strategy. Jacqueline’s project experience spans a broad range of therapeutic areas, although in recent years she has focused on niche indications (including rare and ultra rare diseases) spanning various therapeutic areas.
Prior to consulting Jacqueline gained several years of industry experience, fulfilling two internships at Glaxo Wellcome (now GlaxoSmithKline) and undertaking research drug discovery as a Research Associate at Eisai London Research Laboratories.
Jacqueline holds a MPhil in Bioscience Enterprise (University of Cambridge) and a BSc in Biochemistry (University of Bristol).
Mizuki, a Japanese national from Tokyo, is a Principal Consultant at Datamonitor Consulting. Having joined Datamonitor in 2001, Mizuki brings a broad knowledge of the pharmaceutical industry with a specific focus on the Pacific Rim region.
Based in our Tokyo office, Mizuki holds a client-facing role with our Japanese clients, developing business and ensuring smooth project execution for our Japan-based clients. He also supervises and produces analysis on the Japanese market, run out of our Tokyo offices.
During his time with the company, Mizuki had managed a team of researchers. He has successfully conducted several projects, analyzing clients’ portfolio offerings, providing opportunity assessments, supporting partnering meetings, and generally helping our clients making better informed decisions.
Mizuki holds a BA in Business Administration from the American University in London.
Ellen has over 15 years’ experience in pharmaceuticals, both in the industry and as a consultant. Since joining Datamonitor in 2010, she has focused on clients’ needs in the areas of opportunity assessment and portfolio prioritization. Ellen manages US client relationships out of our offices in New York.
Before joining Datamonitor, Ellen spent four years focused on opportunity assessments and corporate development consulting for small and specialty pharmaceutical companies. Her work as an independent consultant supported the Series A capital raises of three start-up companies totaling $93m.
Before leaving the industry to pursue consulting, Ellen worked at Verus Pharmaceuticals, handling the new product planning of a novel drug/device combination being developed for Asthma and chronic obstructive pulmonary disease. Before that, she spent eight years at Elan Pharmaceuticals in roles of increasing responsibility in the areas of sales, sales analytics, marketing analytics, brand management, global launch planning, and strategic marketing. She led the professional marketing efforts for the global launch of Tysabri in Crohn’s disease and served as the commercial representative on auto-immune pre-IND core teams, assessing the value of candidate compounds and indications.
Ellen holds a BS in Mathematics (Chestnut Hill College) and an MBA (UCLA Anderson School of Management).